newYou can now listen to Fox News articles.
Experimental drug shown to have boosting effect weight loss Studies have shown up to a 20% reduction.
Eloralintide, a once-weekly injection made by Eli Lilly (Indianapolis), produced “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes, according to a press release.
The drug was generally well tolerated by study participants.
Studies have shown that experimental drugs promote weight loss by up to 20%. (St. Petersburg)
The Phase 2 trial was sponsored by Eli Lilly and involved 263 adults. After 48 weeks, they lost between 9.5% and 20.1% of their body weight, compared with 0.4% in the group taking the placebo.
Treatment with eloralintide also led to improvement in waist circumference. blood pressureResearchers say lipid profile, glycemic control, and inflammatory markers can all increase cardiometabolic risk.
Weight loss drug could add years to Americans’ lives, researchers project
“The weight loss observed in this study has clinical implications,” says study lead author and clinical director of medicine Leanna K. Billings, MD. genetics research Endeavor Health in Skokie, Illinois, conducts research in diabetes and cardiometabolic diseases, the company said in a press release.
“When we see this level of weight loss in just 48 weeks, we see people with improvement or resolution of other conditions such as high blood pressure, hyperlipidemia, and osteoarthritis. sleep apnea syndrome Additionally, weight-related symptoms may also occur. ”
Eloralintide, a once-weekly injection made by Eli Lilly of Indianapolis, produced “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes. (Getty Images)
“Furthermore, there was no nadir or plateau in weight loss in this study, so weight loss is expected to continue if the study continues for a longer period of time. Additionally, up to 90% of participants who took eloralintide improved in at least one BMI category,” she added.
The results were published in The Lancet and presented at ObesityWeek 2025 in Atlanta, Georgia, earlier this month.
America’s obese state revealed — and how Ozempic is changing the map
Despite being popular GLP-1 drug – including Ozempic, Wegovy, Mounjaro, and Zepbound – work by mimicking the intestinal hormone GLP-1 (glucagon-like peptide-1). Eloralintide is a selective amylin receptor agonist that works by mimicking a pancreatic hormone called amylin.
Like GLP-1, it slows down digestion and reduces appetite; control blood sugar levels After dinner. It has not yet been approved by the FDA for clinical use.
GLP-1 drugs work by mimicking the intestinal hormone GLP-1, while elolarintide is a selective amylin receptor agonist that works by mimicking a pancreatic hormone called amylin. (St. Petersburg)
The biggest side effects noted with eloralintide were mild to moderate gastrointestinal symptoms and fatigue, the researchers noted. These effects were greater at higher doses.
“Obesity is complex conditionsAnd there is no single treatment that works for everyone,” Billings said.
“To truly meet the needs of each patient, we need treatments with different mechanisms of action so that each person receives a treatment that provides the optimal balance of efficacy and tolerability.”
Could GLP-1 weight loss drugs like Ozempic become a “panacea”?
Based on the results of this study, the researchers: obesity treatment By the end of this year, the president of Lilly Cardiometabolic Health confirmed to Fox News Digital. This drug is also being evaluated in combination with GLP-1 drugs.
Dr. Brett Osborne, a Florida neurosurgeon and longevity expert, shared some concerns about new anti-obesity drugs being developed.
“The bottom line is that if you have an experienced and competent doctor supervising your care and promoting the formation of healthy habits and not just the use of drugs, you will lose weight,” the doctor said. (St. Petersburg)
“Of all the drugs in the world, there is no one person who cannot lose weight when combined with a progressive drug.” resistance training And you need to pay attention to your daily intake of macronutrients, even in small amounts,” a doctor not involved in the study told FOX News Digital.
“Yet, big pharmaceutical companies continue to search for new targets, new drug Perhaps they will prove to be as effective as, if not more effective than, current drugs. There are enough agents to drive weight loss to the point of malnutrition. ”
Click here to download the FOX News app
Osborne also pointed out that the drug’s lower cardiovascular risk was likely due to the participants’ reduced body fat, which reduces their risk of all age-related diseases.
“Some side effects are rare or take time to develop, so it’s important to monitor the safety of new drugs like eloralintide over time.”
“Bottom line: When you have an experienced and competent physician to oversee an individual’s care and drive the shaping of medical care.” healthy habits “It’s not just about using drugs, it’s about losing weight,” he says.
Click here to sign up for our health newsletter
Dr. Sue Decotis, a weight loss physician in New York City, also shared her thoughts on the potential of eloralintide as an alternative treatment.
“It appears that the more receptor systems that are affected, the more weight patients are able to lose,” she told Fox News Digital. “This is tirzepatide (Munjaro, Zepbound) attacked two receptors and caused more weight loss than Ozempic or Wegovy. ”
“To truly meet the needs of each patient, we need treatments with different mechanisms of action so that each person receives a treatment that provides the optimal balance of efficacy and tolerability,” the researchers said. (St. Petersburg)
“In my practice, I have seen that when patients are switched from Ozempic, they have significantly better outcomes with tirzepatide.”
Decotis, who was also not involved in the study, said attacking more receptors could be a solution for patients who don’t respond well or who have “hit a wall” with simpler drugs.
“Peptide drugs are promising when it comes to long-term safety and outcomes,” she said.
Test yourself with our latest lifestyle quiz
Whitney Di Bona, in-house attorney and consumer safety advocate for DrugWatch, said the Phase 2 results are “promising,” but caution is important.
“These drugs have been used for years, but new safety concerns continue to emerge,” a Florida-based expert told FOX News Digital. Some of them contain potentially serious problems eye conditiondelayed gastric emptying, intestinal obstruction, and serious digestive problems have occurred, leading to numerous lawsuits.
For more health stories, click here
“It is important to monitor the safety of new drugs like elolarintide over time, as some side effects are rare or take time to develop,” Di Bona advised. “Even with careful study, some risks may only become apparent after the drug is used by many people.”
